Marstacimab is indicated for:
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Marstacimab is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Marstacimab is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with severe haemophilia B (congenital factor IX deficiency, FIX <1%) without factor IX inhibitors.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.